Clinical disclaimer: This article is educational and does not constitute personal medical advice. Never stop or reduce prescription medication without clinical supervision. If you have acute symptoms, contact your GP or NHS 111.

The scale of the problem

Proton pump inhibitors — omeprazole, lansoprazole, pantoprazole, esomeprazole — are among the most prescribed medications in the UK. An estimated 10% of the adult population takes them regularly, many without a clear ongoing indication. [1] They are initiated in hospital, started for short-term indications, and then repeat-prescribed for years without review. A 2022 audit in NHS England found that 40–60% of PPI prescriptions lacked a documented current clinical indication. [2]

This matters because PPIs are not pharmacologically benign at long-term use. Associations with hypomagnesaemia, B12 deficiency, increased infection risk (including C. difficile), and accelerated chronic kidney disease progression are recognised in pharmacovigilance data and the MHRA has issued guidance on these risks. [3]

When PPIs are and are not justified long-term

Long-term PPI use is clinically justified in: Barrett's oesophagus (indefinite, dose-optimised); confirmed erosive oesophagitis; documented peptic ulcer disease; NSAID or antiplatelet gastroprotection in high-risk patients; and Zollinger-Ellison syndrome. [4]

Long-term PPI use is frequently not justified in: uncomplicated GORD managed initially short-term; dyspepsia without endoscopic findings; started in hospital without indication documented; started alongside medication that has since stopped; or simple reflux symptoms that were never reassessed after lifestyle modification.

Rebound acid hypersecretion: the stopping problem

The main barrier to stopping PPIs is rebound acid hypersecretion. During PPI use, gastrin levels rise (a compensatory response to reduced acid). When the PPI is stopped, gastrin-driven acid secretion rebounds above baseline — often causing significant reflux and heartburn symptoms for two to four weeks that are worse than the original complaint. [5]

This rebound effect causes many patients to conclude the PPI is essential when in fact they are experiencing pharmacological withdrawal. The critical insight: rebound symptoms do not confirm ongoing PPI need — they are a temporary pharmacological phenomenon that resolves if tolerated. However, tolerating four weeks of significant reflux is not always feasible, particularly if the patient is working, sleeping poorly, or has prior oesophageal disease.

Strategies for stopping safely

Step-down approach: reduce dose before stopping rather than stopping at full dose. Full-dose omeprazole (40 mg) → standard dose (20 mg) → every other day → stop. This attenuates the rebound by allowing gastrin to normalise more gradually. The step-down typically takes four to eight weeks. [4]

H2 blocker bridge: switch from a PPI to an H2 blocker (famotidine, available OTC in the UK) during the final stopping phase. H2 blockers do not cause the same rebound effect as PPIs, and can be tapered more easily. This reduces the intensity of rebound symptoms while the PPI clears.

On-demand prescribing: rather than daily use, some patients can manage well with intermittent dosing — taking a PPI only during symptomatic periods. This is appropriate for intermittent GORD symptoms but not for Barrett's or high-risk erosive disease.

Timing: start the step-down during a lower-stress period with access to evening antacids (Gaviscon, alginate preparations) as symptom relief during the rebound phase.

What to address alongside stopping

Rebound reflux is more severe if the lifestyle drivers of reflux have not been addressed. Before or during step-down: avoid food within three hours of lying down; reduce portion sizes particularly at evening meals; reduce alcohol, coffee, and high-fat meals (all of which slow gastric emptying and increase reflux opportunity); review any medications that reduce lower oesophageal sphincter tone (calcium channel blockers, nitrates, some antidepressants); and address obesity, which increases intra-abdominal pressure. Weight loss significantly reduces reflux burden — a fact directly relevant to patients stopping GLP-1 medication who may have experienced improved reflux during treatment and now face its return with weight regain. See GLP-1 reflux and gut symptoms.

When not to stop PPIs

Do not attempt PPI deprescribing independently if you have: known Barrett's oesophagus; history of peptic ulcer disease; are on anticoagulants or dual antiplatelet therapy; or have had significant upper GI bleeding. These require a clinician-led decision with endoscopic follow-up where appropriate. [4]

FAQ

Is it safe to stop PPIs suddenly?
Not recommended. Rebound acid hypersecretion — caused by elevated gastrin levels during PPI use — can produce significant reflux and heartburn for two to four weeks after stopping. A step-down approach over four to eight weeks significantly reduces this rebound effect and is the recommended strategy.
How do I stop taking omeprazole?
Step down gradually: full dose → half dose → alternate days → stop, over four to eight weeks. Using an H2 blocker (famotidine) as a bridge during the final phase can reduce rebound symptoms. Address lifestyle drivers of reflux — late meals, alcohol, large portions, lying flat after eating — before stopping.
Will my reflux come back after stopping PPIs?
Rebound reflux is common in the first two to four weeks regardless of whether you had reflux before treatment — it is a pharmacological withdrawal effect from gastrin rebound, not confirmation that the PPI was necessary long-term. If symptoms resolve after four weeks, the PPI may not have been addressing an ongoing condition. If significant symptoms persist beyond six weeks, reinvolve your GP.
What does NICE say about stopping PPIs?
NICE CG17 (dyspepsia) recommends that PPI prescriptions be reviewed regularly and that step-down or on-demand strategies be used for uncomplicated GORD rather than indefinite full-dose prescribing. Long-term PPI use is endorsed only for specific indications including Barrett's oesophagus, erosive oesophagitis, and NSAID gastroprotection in high-risk patients.
Do PPIs cause long-term harm?
Long-term PPI use is associated with several recognised risks: hypomagnesaemia, B12 deficiency, increased C. difficile infection risk, and associations with chronic kidney disease progression and dementia in observational data. The MHRA has issued safety guidance on hypomagnesaemia and B12. These associations do not mean PPIs cause harm in all patients — they mean the risk-benefit analysis should be revisited regularly, particularly for patients without a clear ongoing indication.

References

  1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008.
  2. NHS England. Medicines optimisation: PPI prescribing audit. 2022.
  3. MHRA. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus; risk of hypomagnesaemia with prolonged use. Drug Safety Update. 2023.
  4. NICE. Gastro-oesophageal reflux disease and dyspepsia in adults. CG17. 2014 (updated 2023).
  5. Reimer C et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009.